You do know that you made a legally actionable libelous comment about tweeter, right?
I can see why people report you to a yahoo.
He is right about the Verigene Enteric Pathogens panel NOT detecting Ebola. This is copied and pasted directly from the FDA clearance documents and the NSPH website:
"For in vitro Diagnostic Use
TARGETS US/FDA Cleared Outside US
Campylobacter Group X X
Salmonella spp. X X
Shigella spp. X X
Vibrio Group X X
Yersinia enterocolitica X X
Shiga Toxin 1 (stx1) X X
Shiga Toxin 2 (stx2) X X
Norovirus X X
Rotavirus X X"
Ebola IS NOT part of the Verigene test and NSPH has NO Ebola test.
I suggest to check out NSPH's own website before you post more nonsense.
Sentiment: Strong Sell
NSPH DOES not HAVE an Ebola test. In fact, I invite you to check their website where Ebola is not mentioned ANYWHERE.
Sentiment: Strong Sell
Two days after you claimed you were done here and would no longer post here, yet you are still here spamming your derogatory bile.
Please get some help.
You seem unable to tell the truth. C. difficile is a bacteria that not only causes GI problems but that can also kill. And both their Strep and Strep B tests are for bacteria too.
The two companies ARE competitors, not complimentary.
When you stated that QDEL only had a viral pathogens test, not bacterial, you clearly showed you don't know what you are talking about.
QDEL already markets molecular tests for the following:
Group B Strep
As you can see, their tests cover BACTERIAL and viral disease, including some enteric/gastric as well as multiple respiratory viruses (not just flu) and sexually transmitted disases.
Please stop posting nonsense here.
You already disproved your hypothesis since QDEL has a competitor test(s) to NSPH's and has no need for their technology since it already has its own established molecular diagnostics program.
Damned you! You just made me laugh so hard while trying to sip hot coffee that I spewed it out of my nose all over my desk and almost choked!
Agreed. I have seen this many times before in the molecular Dx business. The people trying to fool themselves into believing the company will actually "merge" with another are delusional. NSPH will be acquired and then disassembled.
And you are also right about the employees and anyone not holding preferred shares being screwed. This has been seen over and over again when small molbio manufacturers are sold. The corporate officers and largest institutional investors always have those preferred shares paid out well above what the closing price was the day of the acquisition while the common share holders, including retail holders, employees having company shares obtained through employee stock purchase programs, employees having incentive stock options or restricted stock units get nothing since most, if not all, of those shares are underwater at the acquisition price.
Sammyjammin is correct. This is truly the death knell.
No, the message board forum gives you an avenue to continue to harass time and time again, as you just pointed out to Yahoo.
Since harassment is a Yahoo Terms of Service violation, I imagine that they will be taking action against you.
Albert Einstein said the definition of insanity is doing something over and over again and expecting a different result.
He was apparently talking about you.
You keep saying "we". Are you referring to your other personalities/alter egos or the voices in your head that talk to you?
here is what the editorial about the studies published yesterday in the NEJM said about the test...
"Second, it would appear that, despite the variation in trial design, these trials indicate that this pharmacogenetic testing has either no usefulness in the initial dosing of vitamin K antagonists or, at best, marginal usefulness, given the cost and effort required to perform this testing."
From today's NEJM...
Embargoed for Release: Tuesday, November 19, 2013, 11:45 a.m. EST
Genetic data does not improve anticoagulation control with warfarin
NIH-funded study shows genotyping adds no benefit when added to a clinically-guided dosing formula
Combining genetic data with clinical information to determine the initial dosage of the blood thinner warfarin, used to prevent blood clots in the circulatory system, was no more effective in achieving stable anticoagulation than using only clinical information, according to a National Institutes of Health-funded clinical trial. In addition, the study found that in African-Americans, anticoagulation control was lower in the genetics-based approach compared to the clinically-based method.
The results of the Clarification of Optimal Anticoagulation through Genetics (COAG) trial, supported by the NIH's National Heart, Lung, and Blood Institute, were presented today at the American Heart Association (AHA) Scientific Sessions in Dallas. The study was published simultaneously in the New England Journal of Medicine.
$2.4M revenues misses average Wall Street estimates of $2.6M.
Losses were 0.16 per share when analysts, on average, had estimated a 0.15 loss per share
Sentiment: Strong Sell
A 510(k) submission requires user fees, so it looks like the FDA HAS NOT even accepted SQNM's submission for review.